Cargando…

Efficacy and Safety of a Strategy for Reviewing Intravenous Antibiotics for Hospitalized Japanese Patients with Uncomplicated Diverticulitis: A Single-center Observational Study

OBJECTIVE: Treatment for uncomplicated diverticulitis (UD) is not well established. We evaluated the strategy of reviewing intravenous antibiotics for hospitalized Japanese patients with UD. METHODS: Treatment was based on the physician's choice until August 2018; the indications for hospitaliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Soma, Kazumasa, Nakamatsu, Dai, Nishida, Tsutomu, Minoura, Yutaro, Park, Miyoung, Sugio, Ryo, Okamoto, Akino, Sakamoto, Tatsuya, Tsujii, Yuri, Yamaoka, Sho, Osugi, Naoto, Sugimoto, Aya, Mukai, Kaori, Matsumoto, Kengo, Yamamoto, Masashi, Hayashi, Shiro, Nakajima, Sachiko, Fukui, Koji, Inada, Masami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790783/
https://www.ncbi.nlm.nih.gov/pubmed/35527022
http://dx.doi.org/10.2169/internalmedicine.9361-22
Descripción
Sumario:OBJECTIVE: Treatment for uncomplicated diverticulitis (UD) is not well established. We evaluated the strategy of reviewing intravenous antibiotics for hospitalized Japanese patients with UD. METHODS: Treatment was based on the physician's choice until August 2018; the indications for hospitalization and treatment have been standardized since September 2018. In this study, we monitored the use of intravenous antibiotics administered to patients hospitalized for UD and then reviewed the need for them on hospital day 3. We compared patients' length of antibiotic use, hospital stay, health care cost, and complications via the review strategy from September 2018 to December 2020 and via the previous physicians' choice strategy from January 2016 to August 2018. RESULTS: Two hundred and forty-seven patients were admitted to our hospital because of acute colonic diverticulitis from January 2016 to December 2020. After excluding complicated cases, 106 individuals were enrolled during the period of physician's choice; 87 were enrolled when treatment review was employed. There were no significant differences in age, sex, inflammation site, or severity during the first hospital visit. The median duration of antibiotic use was significantly reduced from 5 to 4 days (p=0.0075), with no marked increase in rates of transfer to surgery, mortality, or readmission due to recurrence. A more significant proportion of patients completed 3-day antibiotic treatment with the review strategy than with the physician's choice strategy (6.6% vs. 25.3%, p=0.0004). However, the length of hospital stay and total medical costs did not decrease. CONCLUSION: The strategy of reviewing treatment on day 3 after hospitalization for UD safety reduced the duration of antibiotic use, but the hospital stay and health care costs did not decrease.